









Markets
/
Stocks
/
nasdaq-bfrg
/

BullFrog AI Holdings, Inc.

BFRG

1.320USD

-0.030-2.22%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

12.71MMarket Cap

LossP/E TTM



BullFrog AI Holdings, Inc.

1.320

-0.030-2.22%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

246 / 506

Overall Ranking

402 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Bullfrog AI Holdings, Inc. is a technology-enabled drug development company. The Company is focused specifically on advanced artificial intelligence / machine learning (AI/ML) analysis of complex data in the advancement of medicine. The Company’s platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational research and development and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. Its siRNA targets Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma (HCC), obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 151.16.

Overvalued

The company’s latest PE is -1.75, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 2.87M shares, decreasing 21.45% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 151.51K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 7.60, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.60

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.28

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.50

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.44

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -1.79, which is 51.06% below the recent high of -2.70 and -123.67% above the recent low of -4.00.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 246/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.03, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 1.49 and the support level at 1.15, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.03

Change

-0.1

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.033

Neutral

RSI(14)

51.392

Neutral

STOCH(KDJ)(9,3,3)

59.245

Sell

ATR(14)

0.085

High Vlolatility

CCI(14)

72.755

Neutral

Williams %R

32.353

Buy

TRIX(12,20)

0.068

Sell

StochRSI(14)

14.186

Oversold

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

1.339

Sell

MA10

1.322

Sell

MA20

1.270

Buy

MA50

1.340

Sell

MA100

1.523

Sell

MA200

1.847

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 30.48%, representing a quarter-over-quarter decrease of 2.17%. The largest institutional shareholder is The Vanguard, holding a total of 151.51K shares, representing 1.46% of shares outstanding, with 2.27% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Singh (Vininder)

2.34M

-2.09%

Tivoli Trust

54.72K

+0.00%

The Vanguard Group, Inc.

Star Investors

151.51K

+22.04%

Geode Capital Management, L.L.C.

53.84K

+14.33%

Fortem Financial Group, LLC

50.00K

-1.19%

Saglio (Dane R)

47.14K

J.W. Cole Advisors, Inc.

39.05K

Raymond James & Associates, Inc.

15.00K

Susquehanna International Group, LLP

13.86K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.08, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.